[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted...

GH : 163.34 (+2.01%)
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

GH : 163.34 (+2.01%)
GEVO : 1.5400 (+0.65%)
COHR : 287.47 (-6.19%)
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

GH : 163.34 (+2.01%)
Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

GH : 163.34 (+2.01%)
Guardant Health: Q2 Earnings Snapshot

Guardant Health: Q2 Earnings Snapshot

GH : 163.34 (+2.01%)
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth...

GH : 163.34 (+2.01%)
Guardant Health Earnings: Analysts Expect Another Loss, But Revenue Growth Tells a Different Story

Barchart Research What to Expect from GH Earnings GH Generated July 29, 2026 Current Price $144.16 EPS Estimate $$-0.74 Consensus Rating Strong Buy Average Move 10.12% Guardant Health Earnings: Analysts...

GH : 163.34 (+2.01%)
Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord...

GH : 163.34 (+2.01%)
Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

GH : 163.34 (+2.01%)
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

Dempsey is calling on Americans to prioritize getting screened and highlighting the innovative Shield blood test for CRC screening Guardant's Shield blood...

GH : 163.34 (+2.01%)

Barchart Exclusives

This High-Yield Exchange Stock Just Raised Its Dividend by Nearly 20%
Cboe Global Markets raised its quarterly dividend by 19% to $0.86 per share on Aug. 13, marking the 16th consecutive year of increases, supported by strong options trading volumes and solid second-quarter results. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.